| Deal value | $30M |
|---|---|
| Share of market cap | 23.8% |
Key highlights
- Priced 18,750,000 shares of common stock at $1.60 per share
- Expects approximately $27.7 million in net proceeds after fees and expenses
- Granted underwriters a 30-day option to purchase up to 2,812,500 additional shares
- Mandatory $15 million prepayment to Perceptive Credit Holdings IV, LP
- Successful closing will trigger Amendment No. 6 to reduce revenue covenants
What Is the Capital Raise?
Neuronetics, Inc. entered into an underwriting agreement with William Blair & Company, L.L.C. to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The transaction, which is expected to close on November 12, 2026, aims to generate gross proceeds of $30 million. The company has also granted the underwriters a 30-day option to purchase an additional 2,812,500 shares on the same terms. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.
Use of Proceeds
- Repayment of a portion of the outstanding term loans under the Perceptive Credit Facility
- A minimum $15 million mandatory prepayment to satisfy Amendment No. 6 conditions
- Funding for sales and marketing initiatives to drive NeuroStar TMS adoption
- Continued research and development activities for interventional mental health technologies
- Financing of potential acquisitions or the establishment of healthcare practices
- General corporate purposes, including working capital and capital expenditures
Strategic Rationale
The offering is a critical component of Neuronetics' strategy to restructure its debt obligations. By satisfying the conditions of the Perceptive Sixth Amendment, which includes a minimum $15 million debt reduction, the company will benefit from lowered revenue covenants. This adjustment is specifically designed to resolve the going concern risk that the company had previously disclosed in its Form 10-Q filings. Strengthening the balance sheet through this equity raise allows the company to maintain its focus on the Greenbrook network of clinics without the immediate pressure of restrictive financial benchmarks.
Financial Context
As of September 30, 2026, Neuronetics had $65 million in aggregate principal outstanding under its Perceptive Credit Facility, which carries an interest rate of 11.5%. The company has been active in managing this debt, having prepaid $5 million of tranche 2 term loans in March 2026. While the company generated $149.1 million in annual revenue, it faces significant volatility, reflected in a 19.4% single-day price drop and a 40.11% weekly decline. This capital raise provides a liquidity cushion as the company matures its interventional psychiatry clinic network toward its 2029 debt maturity date.
Down 22.8% since our story on 12 Nov: $1.62 when we broke it → $1.25 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $1.91 |
|---|---|
| 20 Oct | $1.98 |
| 21 Oct | $2.01 |
| 22 Oct | $2.08 |
| 23 Oct | $2.11 |
| 26 Oct | $2.24 |
| 27 Oct | $2.19 |
| 28 Oct | $2.26 |
| 29 Oct | $2.38 |
| 30 Oct | $2.25 |
| 2 Nov | $2.06 |
| 3 Nov | $2.26 |
| 4 Nov | $2.71 |
| 5 Nov | $2.43 |
| 6 Nov | $2.15 |
| 9 Nov | $2.18 |
| 10 Nov | $2.01 |
| 11 Nov | $1.62 |
| 12 Nov | $1.43 |
| 13 Nov | $1.39 |
| 16 Nov | $1.25 |
| Share price | $1.62 |
|---|---|
| Market cap | $126M |
| Revenue (annual) | $149M |
| 1-month price change | -23.94% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Neuronetics, Inc. announcing an underwriting agreement for a $30 million common stock offering.
Track Neuronetics, Inc. live
Get the next Neuronetics, Inc. SEC filing seconds after it lands.



